Estradiol Cypionate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Estradiol Cypionate
- Estradiol Cypionate: From an Approved Estrogen Injection to Symptomatic Form of Fragile X Syndrome in Female Carrier
Estradiol Cypionate: From an Approved Estrogen Injection to Symptomatic Form of Fragile X Syndrome in Female Carrier
One-Sentence Summary
Estradiol cypionate is a long-acting injectable estrogen, marketed in the US as Depo-Estradiol. The TxGNN model predicts it may be relevant to the symptomatic form of fragile X syndrome in female carriers, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Symptomatic form of fragile X syndrome in female carrier |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (ANDA085470) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Estradiol cypionate is a long-acting estrogen ester given by injection, and estrogen replacement is an established approach for low-estrogen states.
The only plausible link to this prediction is indirect. Female carriers of an FMR1 premutation can develop primary ovarian insufficiency, and estrogen replacement is used to treat the resulting hypoestrogenism. Under that reading, estradiol cypionate would be supportive care for the ovarian complication rather than a treatment for fragile X syndrome itself.
The high TxGNN score (99.69%, model rank 8,278) is not evidence of efficacy. No trials or literature were supplied for this indication, so the link remains a hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered for this indication.
For context, the model’s 6th-ranked prediction, anovulation, returned many trials, but none tested estradiol cypionate. They cover other ovulation-induction agents, estrogen-containing oral contraceptives, diet and diagnostic studies, and do not support this drug directly.
Literature Evidence
Currently no related literature available for this indication.
US Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| ANDA085470 | Depo-Estradiol (Pharmacia & Upjohn Company LLC) | Injection |
The approved indication text was not supplied in the source data.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score, with no trials or publications (Evidence Level L5). The one plausible mechanism, estrogen replacement for FMR1-associated ovarian insufficiency, is indirect and would treat only that complication.
To proceed, the following is needed:
- Mechanism of action data (MOA) for the drug
- Package insert warnings and contraindications, which are required for safety screening
- A targeted literature review of estrogen replacement in FMR1 premutation-associated primary ovarian insufficiency
- Confirmation of the approved indication text for Depo-Estradiol
- Clinical validation before any application, since this is a research-stage prediction and not medical advice
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.